^
+ Follow ENTECAVIR Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 325104
                    [Title] => BFAD okays entecavir for treatment of chronic hepa B
                    [Summary] => Bristol-Myers Squibb has announced that the Bureau of Food and Drugs (BFAD) has approved entecavir for the treatment of chronic hepatitis B virus infection.


The indication is in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

Entecavir is an oral antiviral therapy specifically designed to block the replication of hepatitis B virus (HBV) in the liver. The drug will be available in the Philippines in the first quarter of 2006.
[DatePublished] => 2006-03-09 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 318537 [Title] => BFAD approves entecavir [Summary] => Bristol-Myers Squibb has announced that the Bureau of Food and Drugs (BFAD) has approved entecavir for the treatment of chronic hepatitis B virus infection.

The indication is in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

Entecavir is an oral antiviral therapy specifically designed to block the replication of hepatitis B virus (HBV) in the liver.

The drug will be available in the Philippines in the first quarter.
[DatePublished] => 2006-01-26 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
ENTECAVIR
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 325104
                    [Title] => BFAD okays entecavir for treatment of chronic hepa B
                    [Summary] => Bristol-Myers Squibb has announced that the Bureau of Food and Drugs (BFAD) has approved entecavir for the treatment of chronic hepatitis B virus infection.


The indication is in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

Entecavir is an oral antiviral therapy specifically designed to block the replication of hepatitis B virus (HBV) in the liver. The drug will be available in the Philippines in the first quarter of 2006.
[DatePublished] => 2006-03-09 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 318537 [Title] => BFAD approves entecavir [Summary] => Bristol-Myers Squibb has announced that the Bureau of Food and Drugs (BFAD) has approved entecavir for the treatment of chronic hepatitis B virus infection.

The indication is in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

Entecavir is an oral antiviral therapy specifically designed to block the replication of hepatitis B virus (HBV) in the liver.

The drug will be available in the Philippines in the first quarter.
[DatePublished] => 2006-01-26 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with